SAN FRANCISCO – Coming off a strong 2013 for the biopharma industry, the mood during the 32nd Annual J.P. Morgan Healthcare Conference was enthusiastic – even branching into exuberant – and carried through despite the fatigue that inevitably set in after four days of rapid-fire meetings and presentations.